|
1
|
Bray F, Ferlay J, Soerjomataram I, Siegel
RL, Torre LA and Jemal A: Global cancer statistics 2018: GLOBOCAN
estimates of incidence and mortality worldwide for 36 cancers in
185 countries. CA Cancer J Clin. 68:394–424. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Cisło M, Filip AA, Arnold Offerhaus GJ,
Ciseł B, Rawicz-Pruszyński K, Skierucha M and Polkowski WP:
Distinct molecular subtypes of gastric cancer: From Laurén to
molecular pathology. Oncotarget. 9:19427–19442. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Ma J, Shen H, Kapesa L and Zeng S: Lauren
classification and individualized chemotherapy in gastric cancer.
Oncol Lett. 11:2959–2964. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Dittmar Y and Settmacher U: Individualized
treatment of gastric cancer: Impact of molecular biology and
pathohistological features. World J Gastrointest Oncol. 7:292–302.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Quéro L, Guillerm S and Hennequin C:
Neoadjuvant or adjuvant therapy for gastric cancer. World J
Gastrointest Oncol. 7:102–110. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Roukos DH and Kappas AM: Perspectives in
the treatment of gastric cancer. Nat Clin Pract Oncol. 2:98–107.
2005. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Shirabe K, Shimada M, Matsumata T, Higashi
H, Yakeishi Y, Wakiyama S, Ikeda Y, Ezaki T, Fukuzawa S, Takenaka
K, et al: Analysis of the prognostic factors for liver metastasis
of gastric cancer after hepatic resection: A multi-institutional
study of the indications for resection. Hepatogastroenterology.
50:1560–1563. 2003.PubMed/NCBI
|
|
8
|
Kanat O and O'Neil BH: Metastatic gastric
cancer treatment: A little slow but worthy progress. Med Oncol.
30:4642013. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Wagner AD, Unverzagt S, Grothe W, Kleber
G, Grothey A, Haerting J and Fleig WE: Chemotherapy for advanced
gastric cancer. Cochrane Database Syst Rev. CD0040642010.PubMed/NCBI
|
|
10
|
Wagner AD, Syn NL, Moehler M, Grothe W,
Yong WP, Tai BC, Ho J and Unverzagt S: Chemotherapy for advanced
gastric cancer. Cochrane Database Syst Rev.
8:CD0040642017.PubMed/NCBI
|
|
11
|
Apicella M, Corso S and Giordano S:
Targeted therapies for gastric cancer: Failures and hopes from
clinical trials. Oncotarget. 8:57654–57669. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Lee JS, Kim SH, Im SA, Kim MA and Han JK:
Human epidermal growth factor receptor 2 expression in unresectable
gastric cancers: Relationship with CT characteristics. Korean J
Radiol. 18:809–820. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Liu Y, Ling Y, Qi Q, Zhu M, Wan M, Zhang Y
and Zhang C: Trastuzumab increases the sensitivity of
HER2-amplified human gastric cancer cells to oxaliplatin and
cisplatin by affecting the expression of telomere-associated
proteins. Oncol Lett. 9:999–1005. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Pazo Cid RA and Antón A: Advanced
HER2-positive gastric cancer: Current and future target therapies.
Curr Rev Oncol Hematol. 85:350–362. 2013. View Article : Google Scholar
|
|
15
|
Rodrigues dos Santos C, Domingues G,
Matias I, Matos J, Fonseca I, de Almeida JM and Dias S:
LDL-cholesterol signaling induces breast cancer proliferation and
invasion. Lipids Health Dis. 13:162014. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Huang B, Song B and Xu C: Cholesterol
metabolism in cancer: Mechanisms and therapeutic opportunities. Nat
Metab. 2:132–141. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Göbel A, Rauner M, Hofbauer LC and Rachner
TD: Cholesterol and beyond-the role of the mevalonate pathway in
cancer biology. Biochim Biophys Acta Rev Cancer. 1873:1883512020.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Wang R, Bi J, Ampah KK, Ba X, Liu W and
Zeng X: Lipid rafts control human melanoma cell migration by
regulating focal adhesion disassembly. Biochim Biophys Acta.
1833:3195–3205. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Bathaie SZ, Ashrafi M, Azizian M and
Tamanoi F: Mevalonate pathway and human cancers. Curr Mol
Pharmacol. 10:77–85. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Clendening JW and Penn LZ: Targeting tumor
cell metabolism with statins. Oncogene. 31:4967–4978. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Sharpe LJ and Brown AJ: Controlling
cholesterol synthesis beyond 3-hydroxy-3-methylglutaryl-CoA
reductase (HMGCR). J Biol Chem. 288:18707–18715. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Iannelli F, Lombardi R, Milone MR, Pucci
B, De Rienzo S, Budillon A and Bruzzese F: Targeting mevalonate
pathway in cancer treatment: Repurposing of statins. Recent Pat
Anticancer Drug Discov. 13:184–200. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Ahmadi Y, Ghorbanihaghjo A and Argani H:
The balance between induction and inhibition of mevalonate pathway
regulates cancer suppression by statins: A review of molecular
mechanisms. Chem Biol Interact. 273:273–285. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Yoshioka H, Coates JW, Chua NK, Hashimoto
Y, Brown AJ and Ohgane K: A key mammalian cholesterol synthesis
enzyme, squalene monooxygenase, is allosterically stabilized by its
substrate. Proc Natl Acad Sci USA. 117:7150–7158. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Gill S, Stevenson J, Kristiana I and Brown
AJ: Cholesterol-dependent degradation of squalene monooxygenase, a
control point in cholesterol synthesis beyond HMG-CoA reductase.
Cell Metab. 13:260–273. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Bernstein DL, Le Lay JE, Ruano EG and
Kaestner KH: TALE-mediated epigenetic suppression of CDKN2A
increases replication in human fibroblasts. J Clin Invest.
125:1998–2006. 2015. View
Article : Google Scholar : PubMed/NCBI
|
|
27
|
Dong W, Vuletic S and Albers JJ:
Differential effects of simvastatin and pravastatin on expression
of Alzheimer's disease-related genes in human astrocytes and
neuronal cells. J Lipid Res. 50:2095–2102. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Shen YY, Yuan Y, Du YY and Pan YY:
Molecular mechanism underlying the anticancer effect of simvastatin
on MDA-MB-231 human breast cancer cells. Mol Med Rep. 12:623–630.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Buranrat B, Suwannaloet W and Naowaboot J:
Simvastatin potentiates doxorubicin activity against MCF-7 breast
cancer cells. Oncol Lett. 14:6243–6250. 2017.PubMed/NCBI
|
|
30
|
Lee WS, Chen RJ, Wang YJ, Tseng H, Jeng
JH, Lin SY, Liang YC, Chen CH, Lin CH, Lin JK, et al: In vitro and
in vivo studies of the anticancer action of terbinafine in human
cancer cell lines: G0/G1p53-associated cell cycle arrest. Int J
Cancer. 106:125–137. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Ho PY, Zhong WB, Ho YS and Lee WS:
Terbinafine inhibits endothelial cell migration through suppression
of the Rho-mediated pathway. Mol Cancer Ther. 5:3130–3138. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Vichai V and Kirtikara K: Sulforhodamine B
colorimetric assay for cytotoxicity screening. Nat Protoc.
1:1112–1116. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Riihimäki M, Thomsen H, Hemminki A,
Sundquist K and Hemminki K: Comparison of survival of patients with
metastases from known versus unknown primaries: Survival in
metastatic cancer. BMC Cancer. 13:362013. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Ge S, Xia X, Ding C, Zhen B, Zhou Q, Feng
J, Yuan J, Chen R, Li Y, Ge Z, et al: A proteomic landscape of
diffuse-type gastric cancer. Nat Commun. 9:10122018. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Gunturu KS, Woo Y, Beaubier N, Remotti HE
and Saif MW: Gastric cancer and trastuzumab: First biologic therapy
in gastric cancer. Ther Adv Med Oncol. 5:143–151. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Kim SM and Park SH: Chemotherapy beyond
second-line in advanced gastric cancer. World J Gastroenterol.
21:8811–8816. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Shah MA and Schwartz GK: Cell
cycle-mediated drug resistance: An emerging concept in cancer
therapy. Clin Cancer Res. 7:2168–2181. 2001.PubMed/NCBI
|
|
38
|
Basque JR, Chénard M, Chailler P and
Ménard D: Gastric cancer cell lines as models to study human
digestive functions. J Cell Biochem. 81:241–251. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Clendening JW, Pandyra A, Li Z, Boutros
PC, Martirosyan A, Lehner R, Jurisica I, Trudel S and Penn LZ:
Exploiting the mevalonate pathway to distinguish statin-sensitive
multiple myeloma. Blood. 115:4787–4797. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Caruso MG, Notarnicola M, Cavallini A and
Di Leo A: 3-Hydroxy-3-methylglutaryl coenzyme A reductase activity
and low-density lipoprotein receptor expression in diffuse-type and
intestinal-type human gastric cancer. J Gastroenterol. 37:504–508.
2002. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Kim ST, Kang JH, Lee J, Park HP, Park O,
Park YS, Lim Y, Hwang G, Lee SC, Park KW, et al: Simvastatin plus
capecitabine-cisplatin versus placebo plus capecitabine-cisplatin
in patients with previously untreated advanced gastric cancer: A
double-blind randomized phase 3 study. Eur J Cancer. 50:2822–2830.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Lytras T, Nikolopoulos G and Bonovas S:
Statins and the risk of colorectal cancer: An updated systematic
review and meta-analysis of 40 studies. World J Gastroenterol.
20:1858–1870. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Jones P, Kafonek S, Laurora I and
Hunninghake D: Comparative dose efficacy study of atorvastatin
versus simvastatin, pravastatin, lovastatin, and fluvastatin in
patients with hypercholesterolemia (The CURVES Study). Am J
Cardiol. 81:582–587. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Gerson RJ, MacDonald JS, Alberts AW,
Kornbrust DJ, Majka JA, Subbs R and Bokelman DL: Animal safety and
toxicology of simvastatin and related hydroxy-methyl
glutaryl-Coenzyme A reductase inhibitors. Am J Med. 87:28S–38S.
1989. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Wong WW, Clendening JW, Martirosyan A,
Boutros PC, Bros C, Khosravi F, Jurisica I, Stewart AK, Bergsagel
PL and Penn LZ: Determinants of sensitivity to lovastatin-induced
apoptosis in multiple myeloma. Mol Cancer Ther. 6:1886–1897. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Liao JK and Laufs U: Pleiotropic effects
of statins. Annu Rev Pharmacol Toxicol. 45:89–118. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Mahoney CE, Pirman D, Chubukov V, Sleger
T, Hayes S, Fan ZP, Allen EL, Chen Y, Huang L, Liu M, et al: A
chemical biology screen identifies a vulnerability of
neuroendocrine cancer cells to SQLE inhibition. Nat Commun.
10:962019. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Al-Haidari AA, Syk I and Thorlacius H:
HMG-CoA reductase regulates CCL17-induced colon cancer cell
migration via geranylgeranylation and RhoA activation. Biochem
Biophys Res Commun. 446:68–72. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Chushi L, Wei W, Kangkang X, Yongzeng F,
Ning X and Xiaolei C: HMGCR is up-regulated in gastric cancer and
promotes the growth and migration of the cancer cells. Gene.
587:42–47. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Ebert K, Mattes J, Kunzke T, Zwingenberger
G and Luber B: MET as a resistance factor for afatinib therapy and
motility driver in gastric cancer cells. PLoS One. 14:e02232252019.
View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Sethunath V, Hu H, De Angelis C,
Veeraraghavan J, Qin L, Wang N, Simon LM, Wang T, Fu X, Nardone A,
et al: Targeting the mevalonate pathway to overcome acquired
anti-HER2 treatment resistance in breast cancer. Mol Cancer Res.
17:2318–2330. 2019.PubMed/NCBI
|
